News AbbVie Inc.

Equities

ABBV

US00287Y1091

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:03 2026-03-13 pm EDT			5-day change	1st Jan Change
219.68 ^USD	-2.52%		-4.53%	-3.86%

Mar. 10	AbbVie Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-10-2026 11:20 AM
Mar. 09	AbbVie says CEO Robert Michael's 2025 total compensation was $32.5 million - SEC filing	RE

All News

Mar. 10	AbbVie Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-10-2026 11:20 AM
Mar. 09	AbbVie says CEO Robert Michael's 2025 total compensation was $32.5 million - SEC filing	RE
Mar. 09	AbbVie Announces Positive Topline Results From A Phase 1 Multiple Ascending Dose Study of ABBV-295	CI
Mar. 09	Global drugmakers rush to boost US presence as tariff threat looms	RE
Mar. 09	Global markets live: Live Nation, Eli Lilly, Amazon, Microsoft, ABB…
Mar. 09	AbbVie's Study of Weight-Loss Drug Outperforms Placebo	MT
Mar. 09	Gubra's partner AbbVie reports positive phase 1 results for ABBV-295	RE
Mar. 09	AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults	PR
Mar. 09	Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study	RE
Mar. 05	Illumina, Inc. and Nashville Biosciences, LLC Announce New Proteomics Data Offering and Expansion of Alliance for Genomic Discovery Dataset	CI
Mar. 05	Evercore ISI Adjusts AbbVie Price Target to $233 From $228, Maintains Outperform Rating	MT
Mar. 04	Allergan Aesthetics Shares Medical Weight Loss Data and the Changing Profile of Patients	CI
Mar. 04	When Talk of Talks Moves Markets
Mar. 04	Allergan aesthetics highlights medical weight loss (MWL) data and the changing profile of patients	RE
Mar. 04	ALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA AND THE CHANGING PROFILE OF PATIENTS	PR
Mar. 03	AbbVie Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 11:10 AM
Mar. 03	AbbVie to Present at the Leerink Partners Global Healthcare Conference	PR
Mar. 02	AbbVie's Subcutaneous Skyrizi Meets Co-Primary Efficacy Endpoints in Phase 3 Crohn's Trial	MT
Mar. 02	AbbVie announces positive topline results from phase 3 Affirm study evaluating Skyrizi (risankizumab) subcutaneous induction in patients with Crohn's disease	RE
Mar. 02	AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease	PR
Mar. 02	AbbVie Announces Positive Topline Results from Phase 3 Affirm Study Evaluating SKYRIZI®? (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease	CI
Feb. 25	AbbVie Could See Continued Outperformance Despite Market Concerns, RBC Capital Markets Says	MT
Feb. 25	AbbVie files for seven-part notes offering of up to $8 billion	RE
Feb. 24	AbbVie Plans to Launch Offering of Senior Notes	MT
Feb. 24	AbbVie to Present at the TD Cowen 46th Annual Health Care Conference	PR